Evolus Inc (EOLS) - Total Liabilities
Based on the latest financial reports, Evolus Inc (EOLS) has total liabilities worth $249.43 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Evolus Inc (EOLS) equity growth momentum to track the company's year-over-year net asset growth rate.
Evolus Inc - Total Liabilities Trend (2015–2025)
This chart illustrates how Evolus Inc's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Evolus Inc to measure how efficiently the company converts operating cash flow to free cash.
Evolus Inc Competitors by Total Liabilities
The table below lists competitors of Evolus Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
YG-1 Co. Ltd
KQ:019210
|
Korea | ₩761.54 Billion |
|
Beijing Bashi Media Co Ltd
SHG:600386
|
China | CN¥2.08 Billion |
|
Quad Graphics Inc
NYSE:QUAD
|
USA | $1.10 Billion |
|
Shandong Hiking International Co Ltd Class A
SHG:600735
|
China | CN¥427.87 Million |
|
Horizon Quantum Holdings Ltd. Class A Ordinary Shares
NASDAQ:HQ
|
USA | $23.73 Million |
|
EGing Photovoltaic Technology Co Ltd
SHG:600537
|
China | CN¥4.12 Billion |
|
Dipula Income Fund Ltd
JSE:DIB
|
South Africa | ZAC4.21 Billion |
|
NH SPAC 8
KQ:225570
|
Korea | ₩148.24 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Evolus Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EOLS market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -8.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Evolus Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Evolus Inc (2015–2025)
The table below shows the annual total liabilities of Evolus Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $248.97 Million | +9.66% |
| 2024-12-31 | $227.05 Million | +8.28% |
| 2023-12-31 | $209.69 Million | +31.48% |
| 2022-12-31 | $159.48 Million | -9.18% |
| 2021-12-31 | $175.61 Million | -37.73% |
| 2020-12-31 | $282.03 Million | +75.19% |
| 2019-12-31 | $160.99 Million | +84.07% |
| 2018-12-31 | $87.46 Million | -61.60% |
| 2017-12-31 | $227.78 Million | +169.24% |
| 2016-12-31 | $84.60 Million | +22.08% |
| 2015-12-31 | $69.30 Million | -- |
About Evolus Inc
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels,… Read more